Vividion Therapeutics
4 known investors
Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins. The company operates across the full drug development spectrum from discovery to clinical development.
AI & Machine LearningBiotechDeep Tech
Founders & leadership
BC
Ben CravattScientific Founder
PB
Phil BaranScientific Founder
JY
Jin-Quan YuScientific Founder
Investors · 4
In the news
- Vividion Therapeutics - 2026 Company Profile, Funding & Competitors - Tracxntracxn.com · 2021
- Bayer Acquires Vividion Therapeutics for up to $2B | Precision Medicine Onlineprecisionmedicineonline.com · 2021
- Jeff Hatfield assembles a syndicate with some A-list public investors in the mix as Vividion adds $135M raiseendpoints.news · 2021
- San Diego biotech Vividion raises $82 million – San Diego Union-Tribunesandiegouniontribune.com · 2019
- Vividion Raises $82M to Advance Small Molecule Drugs to the Clinic - ManagedLab Servicesmanagedlab.com · 2019
- Vividion Therapeutics Raises $50M in Series A Financing - FinSMEsfinsmes.com · 2017